At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 81 enrolled
Drug / intervention
Colchicine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV
In Brief
A Phase 2 clinical trial evaluating Colchicine and Placebo for Coronary Artery Disease and Human Immunodeficiency Virus. Completed, enrolled 81 participants across 1 site.
Detailed Summary
The investigators are studying whether an anti-inflammatory intervention improves impaired coronary endothelial function (CEF) in HIV+ people with no clinical coronary artery disease (CAD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartNov 2015
First PostedDec 2015
Primary CompletionAug 2020
Study CompletionSep 2020
TodayJul 2026
First PostedDec 8, 2015
Enrollment StartNov 1, 2015
Primary CompletionAug 1, 2020
Study CompletionSep 1, 2020
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 10.6 years ago
Interventions
Colchicinedrug
Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.
Placebodrug
A substance containing no medication